专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012072715A3 USE OF PROKARYOTIC SPHINGOSINE-1-PHOSPHATE LYASES AND OF SPHINGOSINE-1-PHOSPHATE LYASES LACKING A TRANSMEMBRANE DOMAIN FOR TREATING HYPERPROLIFERATIVE AND OTHER DISEASES 审中-公开
公开(公告)号：WO2012072715A3
公开(公告)日：2012-06-07
申请号：PCT/EP2011/071446
申请日：2011-11-30
申请人： UNIVERSITÄT ZÜRICH , UNIVERSITÄT BERN , ZANGEMEISTER-WITTKE, Uwe , HUWILER, Andrea , GRÜTTER, Markus G. , BOURQUIN, Florence
发明人： ZANGEMEISTER-WITTKE, Uwe , HUWILER, Andrea , GRÜTTER, Markus G. , BOURQUIN, Florence
IPC分类号： A61K38/51 , A61P35/00
摘要： The present invention relates to the use of prokaryotic sphingosine-1 -phosphate lyases (S1PL) and S1PLs that lack a transmembrane domain or of a nucleic acid encoding such an S1PL in the prevention or treatment of a disease condition associated with elevated levels of sphingosine-1 -phosphate (S1P), and for which S1P elevation is directly or indirectly causative. In addition, the invention relates to a new product in the form of S1PL lacking the N-terminal loop domain.

2. 发明申请

WO1998003537A2 COMPLEX CRYSTAL FORM 审中-公开
标题翻译：复合晶体形式
公开(公告)号：WO1998003537A2
公开(公告)日：1998-01-29
申请号：PCT/EP1997003990
申请日：1997-07-23
申请人： NOVARTIS AG , MITTL, Peer , DI MARCO, Stefania , GRÜTTER, Markus
发明人： NOVARTIS AG
IPC分类号： C07K00/00
CPC分类号： C12N9/6445 , C07K5/123 , C07K14/815
摘要： The invention relates to crystals of the hirustasin/kallikrein-complex, methods for their production and the use of said crystals or the structure in drug design.
摘要翻译：本发明涉及水杉素/激肽释放酶复合物的晶体，其生产方法以及所述晶体或药物设计中的结构的使用。

3. 发明申请

WO1996018734A1 PRODUCTION OF RECOMBINANT SECRETORY COMPONENT 审中-公开
标题翻译：生产重组分泌成分
公开(公告)号：WO1996018734A1
公开(公告)日：1996-06-20
申请号：PCT/EP1995004797
申请日：1995-12-06
申请人： CIBA-GEIGY AG , VAN OOSTRUM, Jan , ASSELBERGS, Fredericus, Alphonsus, Maria , LEIST, Christian , GRÜTTER, Markus
发明人： CIBA-GEIGY AG
IPC分类号： C12N15/12
CPC分类号： C07K14/47 , A61K38/00
摘要： The current invention relates to a recombinant secretory component (rSC) obtainable from a Chinese Hamster Ovary (CHO) cell that can be crystallized and, hence, is susceptible to systematic studies of its 3-dimensional structure. The crystallized form may be used directly or indirectly (e.g. via the derived structure) for lead finding, screening and binding studies.
摘要翻译：本发明涉及可从结构化的中国仓鼠卵巢（CHO）细胞获得的重组分泌成分（rSC），因此易于对其三维结构进行系统的研究。结晶形式可以直接或间接使用（例如通过衍生结构）用于铅测定，筛选和结合研究。

4. 发明申请

WO1998006833A2 CRYSTAL STRUCTURE OF CPP32 审中-公开
标题翻译： CPP32的晶体结构
公开(公告)号：WO1998006833A2
公开(公告)日：1998-02-19
申请号：PCT/EP1997004268
申请日：1997-08-05
申请人： NOVARTIS AG , MITTL, Peer , DI MARCO, Stefania , GRÜTTER, Markus
发明人： NOVARTIS AG
IPC分类号： C12N09/64
CPC分类号： C12N9/6475
摘要： The present invention relates to the death protease CPP32 in crystallized form and a method for the preparation thereof. The invention further provides a three-dimensional model of CPP32 and improved means for the design of CPP32 modulators.
摘要翻译：本发明涉及结晶形式的死亡蛋白酶CPP32及其制备方法。本发明还提供了CPP32的三维模型和用于设计CPP32调制器的改进方法。

5. 发明申请

WO1997022626A1 LDTI CRYSTALS 审中-公开
标题翻译： LDTI水晶
公开(公告)号：WO1997022626A1
公开(公告)日：1997-06-26
申请号：PCT/EP1996005363
申请日：1996-12-03
申请人： NOVARTIS AG , UCP GEN-PHARMA AG , DI MARCO, Stefania , GRÜTTER, Markus
发明人： NOVARTIS AG , UCP GEN-PHARMA AG
IPC分类号： C07K14/81
CPC分类号： C07K14/811
摘要： The invention relates to LDTI (Leech Derived Tryptase Inhibitor) crystals, methods for their production and slow release formulations comprising these crystals. Also embraced is the use of said crystals or the structure for drug design.
摘要翻译：本发明涉及LDTI（水蛭衍生的类胰蛋白酶抑制剂）晶体，其生产方法和包含这些晶体的缓释制剂。还包括使用所述晶体或用于药物设计的结构。

6. 发明申请

WO1997005166A1 TRANSFORMING GROWTH FACTOR BETA CRYSTALS 审中-公开
标题翻译：转化生长因子结晶
公开(公告)号：WO1997005166A1
公开(公告)日：1997-02-13
申请号：PCT/EP1996003140
申请日：1996-07-17
申请人： CIBA-GEIGY AG , MITTL, Peer , GRÜTTER, Markus , ARVINTE, Tudor
发明人： CIBA-GEIGY AG
IPC分类号： C07K14/405
CPC分类号： C07K14/495 , A61K38/00
摘要： The invention concerns TGF- beta in a crystalline form which shows no adsorption or less adsorption to the wall of vials than the soluted TGF- beta and which is more stable towards oxidative agent tahn the soluted form. TGF- beta crystals of the invention can be used for structure determination and for drug design and for the production of a slow release pharmaceutical preparation.
摘要翻译：本发明涉及结晶形式的TGF-β，其对溶液的TGF-β没有吸附或吸附到小瓶的壁上，并且对于溶解形式的氧化剂更稳定。本发明的TGF-β晶体可用于结构测定和用于药物设计和用于制备缓释药物制剂。

7. 发明申请

WO2009153163A1 CAPILLARY PLATE AND METHOD FOR GROWTH AND ANALYSIS OF MACROMOLECULAR CRYSTALS 审中-公开
标题翻译：毛细管板和大分子晶体的生长和分析方法
公开(公告)号：WO2009153163A1
公开(公告)日：2009-12-23
申请号：PCT/EP2009/056785
申请日：2009-06-03
申请人： UNIVERSITÄT ZÜRICH , BLATTMANN, Beat , GRÜTTER, Markus
发明人： BLATTMANN, Beat , GRÜTTER, Markus
IPC分类号： B01L3/06 , B01D9/00 , C07K1/14 , B01L3/00
CPC分类号： B01L3/06 , B01L3/502738 , B01L2200/0621 , B01L2200/10 , B01L2300/0816 , B01L2300/0819 , B01L2300/0829 , B01L2300/0851 , B01L2300/0864 , B01L2300/087 , B01L2300/168 , B01L2400/0406 , B01L2400/0683 , C30B7/00 , C30B29/58
摘要： The present invention relates to a capillary plate and to a method for growing macromolecular crystals using said capillary plate. The capillary plate allows proteins and other macromolecules to be crystallized by the counter-diffusion method in a restricted geometry. Using this procedure, crystals can be adequately prepared for direct X-ray data analysis such that the macromolecule's three-dimensional structure can be solved without crystal manipulation.
摘要翻译：本发明涉及一种毛细管板和使用该毛细管板生长高分子晶体的方法。毛细管板允许蛋白质和其他大分子在受限制的几何形状中通过反向扩散方法结晶。使用该方法，可以充分准备晶体进行直接X射线数据分析，使得大分子的三维结构可以在没有晶体操作的情况下被解决。

8. 发明申请

WO1993022344A1 PEPTIDE DERIVATIVES CORRESPONDING TO THE CARBOXY TERMINAL SEQUENCE OF HIRUDIN 审中-公开
标题翻译：针对呼吸道的羧基末端序列的肽衍生物
公开(公告)号：WO1993022344A1
公开(公告)日：1993-11-11
申请号：PCT/EP1993000908
申请日：1993-04-15
申请人： CIBA-GEIGY AG , UCP GEN-PHARMA AG , BRUNDISH, Derek, Edward , RINK, Hans , GRÜTTER, Markus , PRIESTLE, John, Peter , SCHMITZ, Albert
发明人： CIBA-GEIGY AG , UCP GEN-PHARMA AG
IPC分类号： C07K15/00
CPC分类号： C07D295/185 , A61K38/00 , C07D211/34 , C07D211/62 , C07K14/815
摘要： Novel compounds of formula (I) in which R and R are hydrogen, C1-C4 alkyl or are linked to form C3-C7 cycloalkyl and R , R and R are the same or different and are hydrogen, C1-C4 alkyl, hydroxy, OR , SR , halogen, NR R , NO2, CN, CONR R or CO2R wherein R is C1-C4 alkyl or C7-C10 aralkyl and R , R and R are the same or different and are hydrogen, C1-C4 alkyl or C7-C10 aralyl or R and R together with the nitrogen atom to which they are bound form 5 or 6 membered azacyloalkyl or oxazacyloalkyl; Arg is arginine [NH-CH(CH2CH2CH2NH-C(=NH)-NH2)-CO]; X is methine CH or nitrogen; n is an integer from 0 to 7; L is a peptide linker, and H is the carboxy terminal end of hirudin, and salts thereof, are provided. The novel compounds are useful for the medical treatment or prevention of thrombosis or diseases caused by thrombosis or can be used for the determination of thrombin in blood as diagnostic reagents.
摘要翻译：式（I）的新型化合物，其中R 1和R 2为氢，C 1 -C 4烷基或连接形成C 3 -C 7环烷基且R 3，R 4和R 5为相同或不同的是氢，C 1 -C 4烷基，羟基，OR 6，SR 6，卤素，NR 7 R 8，NO 2，CN，CONR 7 R 8或CO 2 R 其中R 6为C 1 -C 4烷基或C 7 -C 10芳烷基，R 7，R 8和R 9相同或不同，为氢，C 1 -C 4烷基或C 7 -C 10 芳酰基或R 7和R 8与它们所连接的氮原子一起形成5或6元氮杂烷基或恶唑烷基烷基; Arg是精氨酸[NH-CH（CH 2 CH 2 CH 2 NH-C（= NH）-NH 2）-CO]; X是次甲基CH或氮; n为0〜7的整数; L是肽接头，H是水蛭素的羧基末端及其盐。该新型化合物可用于治疗或预防由血栓引起的血栓形成或疾病，或可用于测定血液中的凝血酶作为诊断试剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式